glp-1 agonists and muscle loss Balancing weight in GLP1 receptor agonist therapy Mechanisms by which GLP-1 agonists

Metabolism (2004) 53:736

Hepatic: Recommendations 9.12 and 9.13a establish GLP-1 RA as preferred therapy for MASH in the context of type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD)

2022;257 doi: 10.1016/j.physbeh.2022.113967

Collectively, this section emphasizes that both membrane-bound and sDPP4 and its inhibition are not only playing an important role in glucose homeostasis but also in several other processes and organs involved in the pathogenesis of T2DM (Figure 2)

Nadler adds

For example, co-morbid conditions like hyperlipidemia could tip the scale and make one drug more suitable for a specific patient